source
- Celldex drops eczema antibody barzolvolimab after Phase 2 failureCelldex Therapeutics said it is ending development of its monoclonal antibody barzolvolimab as a treatment for eczema. The Phase 2 study did not show a statistically significant reduction in itchi…
- FDA leadership search continues as lung cancer drug faces rejection and China’s top drugmakers are rankedThe Readout LOUD podcast this week highlighted three main topics: the FDA’s ongoing search for a new commissioner, a setback for a closely watched lung cancer therapy, and a ranking of China’s bigg…